CAIN CHRISTOPHER W. 4
4 · Jade Biosciences, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Jade Biosciences (JBIO) Director Christopher Cain Receives Option Award
What Happened
Christopher W. Cain, a director of Jade Biosciences (JBIO), was granted a derivative award on 2026-06-09 giving a right to 34,843 shares. The grant shows $0 cash paid and is reported as an award/other acquisition (derivative) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-09; filing date: 2026-06-11 (timely Form 4 filing).
- Award size: option/right for 34,843 shares; reported acquisition price $0.00.
- Vesting: vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting, subject to continued service (Footnote F1).
- Beneficial ownership: the option is held for one or more investment vehicles managed by Fairmount Funds Management LLC; Mr. Cain disclaims beneficial ownership and must turn over net cash/stock to the Fairmount Fund(s) (Footnote F2). Fairmount likewise disclaims beneficial ownership except for pecuniary interest.
- Shares owned after the transaction: not specified in the filing.
Context
This filing reports an equity award (an option/derivative grant), not an immediate stock purchase or sale. The option vests in the future and, per the filing, is held for Fairmount-managed funds rather than for Mr. Cain personally, so the report reflects the grant of rights rather than a direct personal stake being taken or sold.
Insider Transaction Report
Form 4
CAIN CHRISTOPHER W.
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-09+34,843→ 34,843 totalExercise: $15.22Exp: 2036-06-08→ Common Stock (34,843 underlying)
Footnotes (2)
- [F1]This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
- [F2]Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
Signature
/s/ Elizabeth Balta, as attorney-in-fact for Christopher W. Cain|2026-06-11